Arcus Biosciences (NYSE: RCUS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.310 | -0.960 | -0.6500 | ||||
REV | 79.420M | 18.005M | -61.415M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Arcus Biosciences (NYSE: RCUS) through any online brokerage.
Other companies in Arcus Biosciences’s space includes: Twist Bioscience (NASDAQ:TWST), Zentalis Pharmaceuticals (NASDAQ:ZNTL), Sage Therapeutics (NASDAQ:SAGE), Fate Therapeutics (NASDAQ:FATE) and Xencor (NASDAQ:XNCR).
The latest price target for Arcus Biosciences (NYSE: RCUS) was reported by Goldman Sachs on Thursday, May 12, 2022. The analyst firm set a price target for 28.00 expecting RCUS to fall to within 12 months (a possible -2.08% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Arcus Biosciences (NYSE: RCUS) is $28.595 last updated July 5, 2022, 7:59 PM UTC.
There are no upcoming dividends for Arcus Biosciences.
Arcus Biosciences’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Arcus Biosciences.
Arcus Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.